Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Ställberg, Björn ^a   Selroos, Olof ^b   Vogelmeier, Claus ^c   Andersson, Eva ^d   Ekström, Tommy ^d   Larsson, Kjell ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b Semeco ^*  (Sweden)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d ASTRAZENECA R AND D   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; PREDNISOLON RECIP; PREDNISOLONE; SYMBICORT FORTE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEBULIZATION; OUTPATIENT; PATIENT SAFETY; PRIMARY HEALTH CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AMBULATORY CARE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; GERMANY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUESTIONNAIRE; SWEDEN; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AGED; AMBULATORY CARE; BRONCHODILATOR AGENTS; BUDESONIDE; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSPNEA; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SWEDEN; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 65649136231     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-11     Document Type: Article

References (34)

1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
2. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
3. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931. 1747235, 16055622, 10.1136/thx.2005.040527.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: updated 2007. , http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989
5. Niewoehner DE. The role of systemic corticosteroids in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Med 2002, 1(5):243-248. 14720044.
6. Singh JM, Palda VA, Stanbrook MB, Chapman KP. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2002, 162:2527-2536. 10.1001/archinte.162.22.2527, 12456224.
7. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999, 340:1941-1947. 10.1056/NEJM199906243402502, 10379017.
8. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budsonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165:698-703.
9. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007, 29:660-667. 10.1183/09031936.00073506, 17251232.
10. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit Med J 2000, 320:1297-1303. 27372, 10807619, 10.1136/bmj.320.7245.1297.
11. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide and formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. 10.1183/09031936.03.00031402, 12570112.
12. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919. 10.1183/09031936.03.00027003, 14680078.
13. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361(9356):449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
14. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
15. Cazzola M, Salzillo A, De Giglio C, Matera MG, D'Amato G. Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD. Eur Respir J 2003, 22(suppl 45):395s.
16. Cazzola M, Salzillo A, Noschese P, De Giglio C, D'Amato G. Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbation of COPD. Eur Respir J 2004, 24(suppl 48):252s.
17. Cazzola M. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006, 19:79-89. 10.1016/j.pupt.2005.03.004, 15964228.
18. van der Molen T, Willemse BWM, Schokker S, ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and Quality of Life Outcomes 2003, 1/13:1-10. 12773199 , 156640.
19. Kocks JWH, Tuinenga MG, Uil SM, Berg JWK, Ståhl E, Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006, 7:62. 1508149, 16603063, 10.1186/1465-9921-7-62.
20. Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest 2002, 117(suppl 2):398s-401s. 10843984 .
21. Aaron SD, Ferguson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised clinical trials. Thorax 2008, 63:122-128. 10.1136/thx.2007.082636, 17702790.
22. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007, 30:907-913. 10.1183/09031936.00166606, 17715163.
23. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154:407-412.
24. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354:456-460. 10.1016/S0140-6736(98)11326-0, 10465169.
25. Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 2007, 101:1931-1941. 10.1016/j.rmed.2007.04.013, 17544264.
26. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996, 109:1156-1162. 10.1378/chest.109.5.1156, 8625660.
27. Johansson S, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur Respir J 1998, 63(suppl 122):74-82. 6958496 .
28. Broek KM, Wielders PLML, Creemers JPHM, Smeenk FWJM. Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir Med 2008, 102:579-585. 10.1016/j.rmed.2007.11.009, 18222683.
29. Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbations. Eur Respir J 2007, 29:527-534. 10.1183/09031936.00092506, 17107990.
30. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J 2006, 27:877-879.
31. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:760-765. 10.1164/rccm.200404-543OC, 15229100.
32. de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Monteja de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD. Eur Respir J 2006, 27:902-907.
33. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit care Med 1998, 157(suppl 3, pt 2):S1-S53. 9520807 .
34. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003, 16:147-151. 10.1016/S1094-5539(03)00004-X, 12749830.